Respadd, in cooperation with Ofma and the Cep-Addictovigilance Association, has just published a new guide "Opioid Analgesics: What You Need to Know, What You Need to Do". "The unrestricted prescription of anti-disease drugs during the 1990s in the US peaked with the Purdye Pharma campaign on the OxyContin market, coupled with the recovery of heroin, especially black tar, 20 years later, more than 70,000 deaths from annual overdoses, one for every 4,500 inhabitants.This tragedy led the forensic scientist to send letters to doctors prescribing them, telling them that, statistically, one of their patients previously had listing an opioid had died the previous year overdose drugs, "reminds Anne Borgne, president of Respadd, in her introduction to the guide. "This health crisis is an example of the importance of the nurse's independence from the drug industry and the need to address health determinants, enhancing both the patient's health and health skills and knowledge." of all health professionals, "he explains. "By acting on health promotion, a prerequisite for promoting virtuous health behaviors, intervening in a timely manner at risk, promoting autonomy and allowing all up-to-date evidence-based choices." This is the challenge of this new publication by Respadd, offering provide professionals with the information they need for the good use of opioid analgesic drugs in an easily accessible form, highlighting the knowledge and actions that result from it " "Professor Nicolas Authier, director of the French Analgesic Medicines Observatory, reminds his preface in the same book that" opioid analgesics are consumed by some 12 million French people each year. "" Although the exposure to it the drug class has been relatively stable for more than ten years, the development of opiates for opiate intoxication and death is increasing significantly in France, "the doctor notes. He also recalls that the number of French people who received strong opioid analgesics (morphine, fentanyl or oxycodone) almost doubled over the last ten years, mainly for non-cancer-related pain (…) It is the role of each actor to participate to their proper use and to update the French pharmacovigilance system (…) complications associated with these drugs, the most serious of which are dependence or overdose ", hence the issue of this guide attaches great importance to providing health professionals with basic information on these medicines in order to prescribe and accompany the publication of good practice advice ".